Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG

M. Rasche, M. Zimmermann, E. Steidel, T. Alonzo, R. Aplenc, JP. Bourquin, H. Boztug, T. Cooper, AS. Gamis, RB. Gerbing, I. Janotova, JH. Klusmann, T. Lehrnbecher, N. Mühlegger, NV. Neuhoff, N. Niktoreh, L. Sramkova, J. Stary, K. Waack, C. Walter,...

. 2021 ; 13 (10) : . [pub] 20210512

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21017776

Grantová podpora
50-2728, 110244, 70112486 Deutsche Krebshilfe
NCTN Operations Center Grant U10CA180886; NCTN Statistics & Data Center Grant U10CA180899; Chair's Grant U10CA098543 Statistics & Data Center Grant U10CA098413 (2003-2014) NCI NIH HHS - United States
grant agreement 714226 H2020 European Research Council

Post-relapse therapy remains critical for survival in children with acute myeloid leukemia (AML). We evaluated survival, response and prognostic variables following relapse in independent cooperative group studies conducted by COG and the population-based AML-BFM study group. BFM included 197 patients who relapsed after closure of the last I-BFM relapse trial until 2017, while COG included 852 patients who relapsed on the last Phase 3 trials (AAML0531, AAML1031). Overall survival at 5 years (OS) was 42 ± 4% (BFM) and 35 ± 2% (COG). Initial high-risk features (BFM 32 ± 6%, COG 26 ± 4%) and short time to relapse (BFM 29 ± 4%, COG 25 ± 2%) predicted diminished survival. In the BFM dataset, there was no difference in OS for patients who had a complete remission with full hematopoietic recovery (CR) following post-relapse re-induction compared to those with partial neutrophil and platelet recovery (CRp and CRi) only (52 ± 7% vs. 63 ± 10%, p = 0.39). Among 90 patients alive at last follow-up, 87 had received a post-relapse hematopoietic stem cell transplant (HSCT). OS for patients with post-relapse HSCT was 54 ± 4%. In conclusion, initial high-risk features and early relapse remain prognostic. Response assessment with full hematopoietic recovery following initial relapse therapy does not predict survival. These data indicate the need for post-relapse risk stratification in future studies of relapse therapies.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21017776
003      
CZ-PrNML
005      
20210729104019.0
007      
ta
008      
210726s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers13102336 $2 doi
035    __
$a (PubMed)34066095
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Rasche, Mareike $u Department of Pediatric Hematology-Oncology, Pediatrics III, University Hospital of Essen, 45147 Essen, Germany
245    10
$a Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG / $c M. Rasche, M. Zimmermann, E. Steidel, T. Alonzo, R. Aplenc, JP. Bourquin, H. Boztug, T. Cooper, AS. Gamis, RB. Gerbing, I. Janotova, JH. Klusmann, T. Lehrnbecher, N. Mühlegger, NV. Neuhoff, N. Niktoreh, L. Sramkova, J. Stary, K. Waack, C. Walter, U. Creutzig, M. Dworzak, G. Kaspers, EA. Kolb, D. Reinhardt
520    9_
$a Post-relapse therapy remains critical for survival in children with acute myeloid leukemia (AML). We evaluated survival, response and prognostic variables following relapse in independent cooperative group studies conducted by COG and the population-based AML-BFM study group. BFM included 197 patients who relapsed after closure of the last I-BFM relapse trial until 2017, while COG included 852 patients who relapsed on the last Phase 3 trials (AAML0531, AAML1031). Overall survival at 5 years (OS) was 42 ± 4% (BFM) and 35 ± 2% (COG). Initial high-risk features (BFM 32 ± 6%, COG 26 ± 4%) and short time to relapse (BFM 29 ± 4%, COG 25 ± 2%) predicted diminished survival. In the BFM dataset, there was no difference in OS for patients who had a complete remission with full hematopoietic recovery (CR) following post-relapse re-induction compared to those with partial neutrophil and platelet recovery (CRp and CRi) only (52 ± 7% vs. 63 ± 10%, p = 0.39). Among 90 patients alive at last follow-up, 87 had received a post-relapse hematopoietic stem cell transplant (HSCT). OS for patients with post-relapse HSCT was 54 ± 4%. In conclusion, initial high-risk features and early relapse remain prognostic. Response assessment with full hematopoietic recovery following initial relapse therapy does not predict survival. These data indicate the need for post-relapse risk stratification in future studies of relapse therapies.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Zimmermann, Martin $u Department of Pediatric Hematology and Oncology, Hannover Medical School, 30625 Hannover, Germany
700    1_
$a Steidel, Emma $u Department of Pediatric Hematology-Oncology, Pediatrics III, University Hospital of Essen, 45147 Essen, Germany
700    1_
$a Alonzo, Todd $u Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
700    1_
$a Aplenc, Richard $u Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA
700    1_
$a Bourquin, Jean-Pierre $u Division of Pediatric Hematology/Oncology, University Children's Hospital Zurich, CH-8032 Zurich, Switzerland
700    1_
$a Boztug, Heidrun $u St Anna Children's Hospital and Children's Cancer Research Institute, Department of Pediatrics, Medical University of Vienna, 1090 Vienna, Austria
700    1_
$a Cooper, Todd $u Seattle Children's Hospital, Seattle, WA 98105, USA
700    1_
$a Gamis, Alan S $u Children's Mercy Hospitals and Clinics, Kansas City, MO 64108, USA
700    1_
$a Gerbing, Robert B $u Children's Oncology Group, Monrovia, CA 91016, USA
700    1_
$a Janotova, Iveta $u Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, 150 06 Prague, Czech Republic
700    1_
$a Klusmann, Jan-Henning $u Clinic for Pediatrics 1, Martin Luther University Halle-Wittenberg, 06108 Halle, Germany
700    1_
$a Lehrnbecher, Thomas $u Division for Pediatric Hematology and Oncology, Hospital for Children and Adolescents, University Hospital, Goethe University Frankfurt am Main, 60590 Frankfurt, Germany
700    1_
$a Mühlegger, Nora $u St Anna Children's Hospital and Children's Cancer Research Institute, Department of Pediatrics, Medical University of Vienna, 1090 Vienna, Austria
700    1_
$a Neuhoff, Nils V $u Department of Pediatric Hematology-Oncology, Pediatrics III, University Hospital of Essen, 45147 Essen, Germany
700    1_
$a Niktoreh, Naghmeh $u Department of Pediatric Hematology-Oncology, Pediatrics III, University Hospital of Essen, 45147 Essen, Germany
700    1_
$a Sramkova, Lucie $u Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, 150 06 Prague, Czech Republic
700    1_
$a Stary, Jan $u Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, 150 06 Prague, Czech Republic
700    1_
$a Waack, Katharina $u Department of Pediatric Hematology-Oncology, Pediatrics III, University Hospital of Essen, 45147 Essen, Germany
700    1_
$a Walter, Christiane $u Department of Pediatric Hematology-Oncology, Pediatrics III, University Hospital of Essen, 45147 Essen, Germany
700    1_
$a Creutzig, Ursula $u Department of Pediatric Hematology and Oncology, Hannover Medical School, 30625 Hannover, Germany
700    1_
$a Dworzak, Michael $u St Anna Children's Hospital and Children's Cancer Research Institute, Department of Pediatrics, Medical University of Vienna, 1090 Vienna, Austria
700    1_
$a Kaspers, Gertjan $u Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands $u Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, 1105 AZ Amsterdam, The Netherlands
700    1_
$a Kolb, Edward Anders $u Nemours/Alfred I. du Pont Hospital for Children, Wilmington, DE 19803, USA
700    1_
$a Reinhardt, Dirk $u Department of Pediatric Hematology-Oncology, Pediatrics III, University Hospital of Essen, 45147 Essen, Germany
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 13, č. 10 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34066095 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210726 $b ABA008
991    __
$a 20210729104018 $b ABA008
999    __
$a ind $b bmc $g 1676416 $s 1138218
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 13 $c 10 $e 20210512 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
GRA    __
$a 50-2728, 110244, 70112486 $p Deutsche Krebshilfe
GRA    __
$a NCTN Operations Center Grant U10CA180886; NCTN Statistics & Data Center Grant U10CA180899; Chair's Grant U10CA098543 Statistics & Data Center Grant U10CA098413 (2003-2014) $p NCI NIH HHS $2 United States
GRA    __
$a grant agreement 714226 $p H2020 European Research Council
LZP    __
$a Pubmed-20210726

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace